Plain-English translation of NCT06500481 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is comparing two different radiation therapy approaches for a serious condition called leptomeningeal metastasis—when breast cancer or lung cancer spreads to the thin membrane surrounding the brain and spinal cord. One approach uses standard radiation focused on specific areas causing symptoms. The other uses newer proton radiation therapy delivered to the entire space containing the brain and spinal cord. The trial wants to see which approach helps patients live longer and controls the cancer better in the brain and spine.
Leptomeningeal metastasis is a devastating complication of advanced cancer with very poor survival. Doctors are uncertain whether treating only the visible problem areas with standard radiation is better than treating the entire brain and spinal cord space with newer proton therapy. This trial will help answer that question and potentially improve outcomes for future patients.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive one of two radiation approaches. Both involve radiation therapy five days a week for two weeks (10 treatment days total). You'll have imaging scans and possibly spinal fluid samples collected before, during, and after treatment to monitor how the cancer is responding. You may be asked to complete questionnaires about your symptoms and how the treatment is affecting your quality of life. Optional blood samples may also be collected for research purposes.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United States